95162-14-4

Usage

Uses

Used in Organic Synthesis:
4-BROMO-1-TRITYL-1H-PYRAZOLE is used as a building block for the synthesis of complex organic molecules. Its trityl group and bromine atom contribute to its reactivity and make it a versatile component in the construction of a wide range of chemical structures.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-BROMO-1-TRITYL-1H-PYRAZOLE is employed as a precursor for the development of bioactive molecules. Its unique properties allow for the exploration of new therapeutic agents and drug candidates.
Used as a Ligand in Metal-Catalyzed Reactions:
4-BROMO-1-TRITYL-1H-PYRAZOLE is utilized as a ligand in metal-catalyzed reactions, where it can enhance the efficiency and selectivity of these processes. Its presence can facilitate the formation of desired products in organic synthesis, making it a useful tool in the development of new chemical reactions.
Used in the Development of New Drugs:
Due to its potential pharmaceutical applications, 4-BROMO-1-TRITYL-1H-PYRAZOLE is used in the research and development of new drugs. Its unique structure can be leveraged to create molecules with specific biological activities, contributing to the advancement of pharmaceutical science.
Safety Precautions:
Given the potential reactivity and toxicity of 4-BROMO-1-TRITYL-1H-PYRAZOLE, it is crucial to observe proper handling and safety precautions when working with 4-BROMO-1-TRITYL-1H-PYRAZOLE. This includes the use of appropriate personal protective equipment and adherence to established safety protocols to minimize risks associated with its use.

Upstream product

• 2075-45-8 4-bromo-1H-pyrazole 
• 76-83-5 trityl chloride 

Downstream Products

• 191980-58-2 4-(4'-methoxyphenyl)-1-tritylpyrazole 
• 207909-09-9 4-(4-tolyl)-1-trityl-1H-pyrazole 
• 179055-92-6 3-(1-trityl-1H-pyrazol-4-yl)benzaldehyde 
• 919802-97-4 4-phenyl-1-trityl-1H-pyrazole 
• 207909-10-2 4-(1-trityl-1H-pyrazol-4-yl)benzyl bromide 
• 179056-75-8 Cycloheptyl-[4-(1-trityl-1H-pyrazol-4-yl)-benzyl]-amine 
• 179056-38-3 Cycloheptyl-[3-(1-trityl-1H-pyrazol-4-yl)-benzyl]-amine 
• 179054-22-9 1-Cycloheptyl-3-(2,4,6-trimethyl-phenyl)-1-[4-(1-trityl-1H-pyrazol-4-yl)-benzyl]-urea 
• 179054-21-8 1-Cycloheptyl-3-(2,4,6-trimethyl-phenyl)-1-[3-(1-trityl-1H-pyrazol-4-yl)-benzyl]-urea 
• 632297-68-8 methyl N-(tert-butyloxycarbonyl)-4-(1-trityl-1H-pyrazol-4-yl)-L-phenylalaninate 
• 863238-73-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(triphenylmethyl)-1H-pyrazole 
• 936359-90-9 4-(4-fluoro-phenyl)-1-trityl-1H-pyrazole 
• 1253690-76-4 4-(fur-2-yl)-1-tritylpyrazole 
• 1253690-75-3 4-(thiophen-3-yl)-1-tritylpyrazole 

Relevant academic research and scientific papers

INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS

The present invention relates to new inhibitors of Notch signalling pathway and its use in the treatment and/or prevention of cancers.

Scalable 9-Step Synthesis of the Splicing Modulator NVS-SM2

NVS-SM2, the first activator of pre-mRNA splicing, displays remarkable pharmacological in vivo activities in models of spinal muscular atrophy. Herein we describe an improved approach to the synthesis of this compound, which features a convenient introduction of sterically encumbered amine moiety onto a fluoropyridazine intermediate.

Identification and Profiling of Hydantoins - A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-β-d-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.

Efficient and chromatography-free methodology for the modular synthesis of oligo-(1H-pyrazol-4-yl)-arenes with controllable size, shape and steric bulk

A novel methodology to synthesise oligo-(1H-pyrazol-4-yl)-arenes with controllable size, shape and steric bulk from 1-trityl-1H-pyrazol-4-ylboronate pinacol esters. This straightforward and efficient procedure can be applied to a variety of brominated aro

Rhodium/chiral diene complexes in the catalytic asymmetric arylation of β-pyrazol-1-yl acrylates

The asymmetric conjugate addition of arylboronic acids to substituted and unsubstituted β-pyrazol-1-yl (E)-tert-butyl acrylates 4 catalyzed by 5 mol % of the Rh(I)/diene 2a catalyst provided the corresponding addition products in 44-98% yield and 91->99.5

Inverse electron demand diels-alder reactions of 1,2,3-triazines: Pronounced substituent effects on reactivity and cycloaddition scope

A systematic study of the inverse electron demand Diels-Alder reactions of 1,2,3-triazines is disclosed, including an examination of the impact of a C5 substituent. Such substituents were found to exhibit a remarkable impact on the cycloaddition reactivity of the 1,2,3-triazine without altering, and perhaps even enhancing, the intrinsic cycloaddition regioselectivity. The study revealed not only that the reactivity may be predictably modulated by a C5 substituent (R = CO2Me > Ph > H) but also that the impact is of a magnitude to convert 1,2,3-triazine (1) and its modest cycloaddition scope into a heterocyclic azadiene system with a reaction scope that portends extensive synthetic utility, expanding the range of participating dienophiles. Significantly, the studies define a now powerful additional heterocyclic azadiene, complementary to the isomeric 1,2,4-triazines and 1,3,5-triazines, capable of dependable participation in inverse electron demand Diels-Alder reactions, extending the number of complementary heterocyclic ring systems accessible with implementation of the methodology.

Synthesis of 4-aryl-1H-pyrazoles by Suzuki-Miyaura cross coupling reaction between 4-bromo-1H-1-trityl-pyrazole and arylboronic acids

A general procedure for the synthesis of 4-aryl-1H-pyrazoles by the Suzuki-Miyaura cross coupling reaction between 4-bromo-1H-1-tritylpyrazole and commercially available arylboronic acids was developed. Using this procedure, a direct synthesis of 4-aryl-1H-pyrazoles possessing functional groups, such as hydroxyl, nitro, and amino groups, on the aryl ring was realized. Those molecules could not be prepared by our previous synthesis of 4-aryl-1H-pyrazoles via the Kumada cross coupling reaction.

PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME

Anti-fungal agent having excellent anti-fungal action physicochemical properties including safety and water solubility. Compound represented by formula (I), or salt thereof: wherein R1 represents hydrogen, halogen, amino, R11-NH- wherein R11 represents C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkoxy C1-6 alkyl, or C1-6alkoxycarbonyl C1-6 alkyl, R12-(CO)-NH- wherein R12 represents C1-6 alkyl group or C1-6 alkoxy C1-6 alkyl, C1-6 alkyl, hydroxy C1-6 alkyl, cyano C1-6 alkyl, C1-6 alkoxy, or C1-6 alkoxy C1-6 alkyl or a phosphonoamino group; R2 represents hydrogen, C1-6 alkyl, amino, or a di C1-6 alkylamino group or a phosphonoamino group; one of X and Y is nitrogen while the other is nitrogen or oxygen; ring A represents a 5- or 6-member heteroaryl ring or a benzene ring which may have a halogen atom or 1 or 2 C1-6 alkyl groups; Z represents a single bond, a methylene group, an ethylene group, oxygen, sulfur, -CH2O-, -OCH2-, -NH-, -CH2NH-, -NHCH2-, -CH2S-, or -SCH2-; R3 represents hydrogen or halogen or C1-6 alkyl, C3-8 cycloalkyl, C6-10 aryl, a 5- or 6-member heteroaryl group or a 5- or 6-member nonaromatic heterocyclic group which may have 1 or 2 substituents; and R4 represents hydrogen or halogen; provided that either R1 or R2 represents a phosphonoamino group.

Tec Kinase Inhibitors

Disclosed are compounds of formula (I): wherein Q, R1, R2, R3, R4 and R5 are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.

Novel Antifungal Triazole Derivatives

Disclosed herein are antifungal triazole derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The triazole derivatives of Chemical Formula 1 or pharmaceutically accep